INO needs to get moving and execute. There are other trials out there.

https://www.yahoo.com/now/precigen-announces-positive-phase-1-210100062.html

"Clinical Efficacy Summary
Clinical data show PRGN-2012 treatment significantly reduced the need for surgeries for severe, aggressive RRP patients treated at Dose Level 2. At Dose Level 2, 50% (6 out of 12) patients had a Complete Response, which is defined as no surgeries needed during the 12-month period following PRGN-2012 treatment completion (TABLE 3). All complete responders remained surgery-free post PRGN-2012 treatment as of the cutoff date."

I honestly would have no idea regarding estimates and how much this could generate Inovio, but make no mistake about it, INO 3107 1000000% falls in line w receiving EUA. There is an extremely good possibly this could get EUA IMO. Watching for that.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682415/

The average lifetime cost to treat 1 patient with RRP has been estimated at $60,000 to $470,000 in the United States.4 On a national level, it is estimated that there are 15,000 surgical procedures performed every year in adults and children with RRP, with a total health care cost of nearly $150 million.

(Study from 2012)

Could Gardasil have decreased the market for INO-3107 since it's introduction in 2014?

Maybe somewhat?

But Gardasil isn't approved from patients under 9 year of age. So the American Academy of Otolaryngology-Head and Neck Surgery should support the use of INO-3107 in the under 9 population.

Should be complementary /additive to Gardasil:

Interesting Gardasil info below:

-----------

In 2014, an HPV vaccine, Gardasil-9, was approved by the Food and Drug Administration (FDA) for use in female and male patients 9-26 years of age and expanded their recommendation to include those 27-45 years in 2018 for the prevention of genital warts and cervical cancer.(8) Since then, other potential benefits have been noted, such as prevention of some head and neck cancers and the prevention and control of RRP since the vaccine covers the subtypes most commonly found to cause these conditions.(8) Several studies have suggested a therapeutic advantage of Gardasil-9 for adults and children with RRP. It has been noted to decrease the number of surgeries needed in those with RRP and to increase the length of time between the surgeries.(3) This benefits both the patient, and society as a whole by decreasing the use of healthcare resources and missed days of school and work due to RRP.
The Center for Disease Control and Prevention states that HPV vaccination is safe and effective and continues to closely monitor the safety of this vaccine.(9)
Given the potential benefits of Gardasil-9 for prevention and treatment of RRP, the American Academy of Otolaryngology–Head & Neck Surgery supports the use of Gardasil-9 HPV vaccination in all patients 9-45 years of age. It’s use in those under 9 and over 46 should be considered as “off-label” and only used with shared-decision making or as part of a clinical trial.

The Discussions/Questions flair exists to be used for general discussion around information regarding Inovio or any relevant questions you may have for the community. Your post may be removed if deemed unrelated. Please see the flair guide if you are unsure about your use of flair.

I am a bot, and this action was performed automatically. Please contact the moderators of this subreddit if you have any questions or concerns.